TY - JOUR T1 - Comorbidities associated with sarcoidosis – Results from long-term observational study JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P461 AU - Adam Nowinski AU - Elzbieta Puscinska AU - Anna Goljan-Geremek AU - Michal Bednarek AU - Dariusz Kaminski AU - Dorota Gorecka Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P461.abstract N2 - Rationale: Sarcoidosis is a multisystem inflammatory disease of unknown etiology. Sarcoidosis may affect many tissues by the presence of noncaseating granulomas, but the inflammatory process can potentially trigger other comorbidities in sarcoid patients.Aim: The aim of this study was to identify the prevalence of comorbidities in sarcoid patients.Materials and methods: A cohort of 557 patients with histologically confirmed sarcoidosis diagnosed between 2007 and 2011 was observed. All patients were carefully examined for comorbidities.Results: 291 males (52,2%) and 266 females (47,8%) with mean age 48,4 ±12,0 yrs were observed. Majority of studied patients had radiological stage II (62,1%) and stage III (20,8%) of the disease. Stage I was diagnosed in 14,1% patients and extrapulmonary involvement in 32,3% patients.Most frequent of comorbidities were: hyperlipidemia N=121 (21,7%), obesity N=79 (14,2%), thyroid disease N=73 (13,1%), diabetes N=41 (7,4%), bronchiectases N=35 (6,3%), neoplasm N=33 (5,9%), osteoporosis N=32 (5,7%), anaemia N=26 (4,7%), coronary heart disease N=25 (4,5%), asthma N=21 (3,8%), gastric/duodenal ulcer N=16 (2,9%), allergy N=14 (2,5%), sleep apnea N=12 (2,2%), hypertension N=9 (1,6%), chronic renal disease N=6 (1,1%).Conclusion: We have found significant number of comorbidities in patients with sarcoidosis. Screening for these conditions, especially thyroid and neoplastic disorders, should be considered in these patients. ER -